Wellgistics Health, Inc. 8-K

What Happened
Wellgistics Health, Inc. (NASDAQ: WGRX) filed an 8-K on June 12, 2026 reporting two Nasdaq actions. On June 9, 2026 Nasdaq granted the company an extension to regain compliance with the minimum stockholders’ equity requirement after notifying the company on April 13, 2026 that its reported stockholders’ equity of $(12,447,801) as of December 31, 2025 failed to meet Nasdaq Listing Rule 5550(b)(1) (the $2.5 million minimum). The company says it has taken steps — including a binding term sheet with DataVault AI to create DelivMeds AI, an intended acquisition of an intellectual property portfolio, and a planned controlling stake in Tollo Health — and estimates a potential post-transaction stockholders’ equity of about $40 million and combined assets of roughly $4 billion. Separately, Nasdaq notified the company on June 9, 2026 that it had regained compliance with the $1.00 minimum bid price requirement after the closing bid was $1.00+ each business day from May 26 to June 8, 2026.

Key Details

• Deficiency cited: Nasdaq letter (Apr 13, 2026) cited stockholders’ equity of $(12,447,801) vs. $2,500,000 required under Rule 5550(b)(1).
• Nasdaq extension: On June 9, 2026 Nasdaq granted an extension to October 12, 2026 to evidence compliance.
• Compliance options: By Oct 12, 2026 the company must (A) file a public report describing the completed transaction and affirm compliance, or (B) file a public report including a balance sheet no older than 60 days with pro forma adjustments showing compliance. Nasdaq will continue to monitor and could delist if compliance is not evidenced in the company’s next periodic report.
• Bid-price issue resolved: Nasdaq’s Dec 10, 2025 notice on low bid price (below $1.00) was closed on June 9, 2026 after WGRX met the $1.00 close requirement from May 26–June 8, 2026; trading continues on the Nasdaq Global Select Market.

Why It Matters
The extension gives Wellgistics time to complete transactions the company says could materially improve its balance sheet, but the company must provide Nasdaq and the SEC with specific documentation by October 12, 2026 or risk delisting. The resolved bid-price deficiency removes an immediate short-term delisting threat, but the longer-term issue remains the company’s negative equity as of year-end 2025. Investors should watch for firm documentation of completed transactions, a pro forma balance sheet showing compliance, and the company’s 2026 periodic reports to see whether Nasdaq’s equity requirement is permanently satisfied.